Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06274788 · ClinicalTrials.gov registry record
Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven Treatment
A clinical trial of Pediatric ALL and Malnutrition, sponsored by Fresenius Kabi.
- Recruiting
- Registry status
- 40
- Enrollment target
- 10
- Study locations
NCT06274788 is a study of Pediatric ALL and Malnutrition that is actively recruiting participants, run by Fresenius Kabi. The registered enrollment target is 40 participants, below the 1,646-participant average among 21 other Pediatric ALL trials with a reported enrollment target (98% lower). The trial reports 10 study locations across 8 states.
The verdict
NCT06274788, a study of Pediatric ALL and Malnutrition, is actively recruiting participants, sponsored by Fresenius Kabi.
- RECRUITING
- Registry status
- 40 participants
- Enrollment target
- 10
- Study locations
Study Summary
This study will demonstrate safety in pediatric patients with Parenteral Nutrition-Associated Cholestasis treated with Omegaven®, which is indicated as a source of calories and fatty acids in this patient population
Conditions Studied
Interventions
- DRUG Omegaven® (fish oil triglycerides) Injectable Emulsion
Study Locations (10)
California
- Memorial Health Service - Fountain Valley
- University of California Los Angeles - Los Angeles
Texas
- Baylor College of Medicine Houston - Houston
- The University of Texas Health Science Center at San Antonio - San Antonio
Illinois
- The University of Chicago - Chicago
Massachusetts
- Children's Hospital Corporation d/b/a Boston Children's Hospital - Boston
Ohio
- Children's Hospital Medical Center - Cincinnati
Oklahoma
- Board of Regents of the University of Oklahoma Health Sciences Center - Oklahoma City
Tennessee
- Vanderbilt University Medical Center - Nashville
Washington
- Seattle Children's Hospital d/b/a Seattle Children's Research Institute - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2024-12-15 |
| Est. Completion | 2027-03-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06274788
The ClinicalTrials.gov registry entry for NCT06274788 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,646-participant average among 21 other Pediatric ALL trials with a reported enrollment target (98% lower). The listed sponsor is Fresenius Kabi, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Pediatric ALL appearing as the primary indexed condition, and to 1 intervention - of which Omegaven® (fish oil triglycerides) Injectable Emulsion is the first listed.
NCT06274788 reports 10 study locations spanning 8 distinct geographic areas - top geographies include California, Texas, Illinois.
Frequently Asked Questions
What is clinical trial NCT06274788 about?
NCT06274788 is a clinical study titled "Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven Treatment". This study will demonstrate safety in pediatric patients with Parenteral Nutrition-Associated Cholestasis treated with Omegaven®, which is indicated as a source of calories and fatty acids in this patient population
What is the current status of trial NCT06274788?
This trial is currently recruiting. The enrollment target is 40 participants. The study started on 2024-12-15. Estimated completion is 2027-03-01.
What conditions does trial NCT06274788 study?
This clinical trial studies the following conditions: Pediatric ALL, Malnutrition, Parenteral Nutrition Associated Liver Disease (PNALD), Essential Fatty Acid Deficiency.
What interventions are being tested in trial NCT06274788?
The interventions under investigation include: Omegaven® (fish oil triglycerides) Injectable Emulsion (DRUG).
Who is sponsoring clinical trial NCT06274788?
This trial is sponsored by Fresenius Kabi, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06274788 being conducted?
This trial has 10 study locations across California, Illinois, Massachusetts, Ohio, Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pediatric ALL
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Multiphase Optimization Strategy (MOST) for Treating Pediatric Post-traumatic Stress Disorder (PTSD)
RECRUITING · NA
-
PRotein Optimization With eXercise to Improve MUscle Mass and Functional outcomeS
RECRUITING · NA
-
Study of CD19-directed Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia
RECRUITING · Phase 1
-
Using Augmented Reality to Promote Physical Activity in Children With Cerebral Palsy
RECRUITING · NA
-
Feasibility/Acceptability of Attentional-Control Training in Survivors
RECRUITING · NA
-
Pharmacokinetics of Drugs Administered to Children
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.